ARCHER 1050, trial summary

A randomised clinical trial investigating the effect of dacomitinib versus gefitinib in Patients (pts) with newly diagnosed stage IIIB/IV/ recurrent NSCLC harboring an EGFR- activating mutation (exon 19 del or exon 21 L858R mu +/- exon 20 T790M mu)

        Z

NCT01774721    Lancet Oncol 2017;18:1454-1466  



Studied treatment dacomitinib
Control treatment gefitinib



Patients Patients (pts) with newly diagnosed stage IIIB/IV/ recurrent NSCLC harboring an EGFR- activating mutation (exon 19 del or exon 21 L858R mu +/- exon 20 T790M mu)
Group sizes-9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint IRC PFS Design



EndpointX1N1X0N0TE95% CI0,22,01,0

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:1454-1466     [PMID: 28958502]   link to pdf   add to Mendeley  

Links

ASCO abstract

ASCO 2018 OS

ASCO 2018 OS

ClinicalTrial.gov record NCT01774721



Registering number NCT01774721 (see trial on clinicaltrials.gov)
Code Name